Elevated Expression of LGR5 and WNT Signaling Factors in Neuroblastoma Cells With Acquired Drug Resistance

Cancer Invest. 2023 Feb;41(2):173-182. doi: 10.1080/07357907.2022.2136682. Epub 2022 Nov 7.

Abstract

Neuroblastoma (NB) is a pediatric solid cancer with high fatality, relapses, and acquired resistance to chemotherapy, that requires new therapeutic approaches to improve survival. LGR5 is a receptor that potentiates WNT/signaling pathway and has been reported to promote development and survival in several adult cancers. In this study we investigated LGR5 expression in a panel of NB cell lines with acquired resistance to vincristine or doxorubicin. We show LGR5-LRP6 cooperation with enhanced expression in drug resistant NB cell lines compared to parental cells, suggesting a role for LGR5 in the emergence of drug resistance, warranting further investigation.

Keywords: LGR5; LRP6; WNT pathway; acquired drug resistance; neuroblastoma.

MeSH terms

  • Cell Line, Tumor
  • Child
  • Drug Resistance, Neoplasm
  • Humans
  • Neoplasm Recurrence, Local
  • Neuroblastoma* / drug therapy
  • Neuroblastoma* / genetics
  • Neuroblastoma* / metabolism
  • Receptors, G-Protein-Coupled / genetics
  • Receptors, G-Protein-Coupled / metabolism
  • Receptors, G-Protein-Coupled / therapeutic use
  • Wnt Proteins / therapeutic use
  • Wnt Signaling Pathway*

Substances

  • Wnt Proteins
  • Receptors, G-Protein-Coupled
  • LGR5 protein, human